2025 Oncologic Emergency Medicine Conference – Past, Present and Future (Hybrid Format) – MDA – Continuing Education (CE)

MDA, 2025 Oncologic Emergency Medicine Conference – Past, Present and Future (Hybrid Format), 2/7/2025 8:30:00 AM – 2/8/2025 4:30:00 PM, This conference aims to continue to fill the knowledge gap in Oncologic Emergency Medicine by providing information in an interactive forum that in turn enhances medical decision-making by healthcare providers working in an acute care setting.

Read the full article here

Source: mdanderson.cloud-cme.com

Categories: Oncologists1, General Medicine News

Tags: endcancer

Tweets with this article

MD Anderson Cancer Center

Register now for the 2025 Oncologic Emergency Medicine Conference, to be held on Feb. 7-8, 2025. This conference aims to enhance medical decision-making by healthcare providers working in an acute care setting. Learn more: https://t.co/d6a6ilyyBp #EndCancer

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC

The EMA’s CHMP has recommended the approval of belzutifan monotherapy for patients with select VHL disease–associated cancers.

OncLive.com January 5, 2025

ctDNA, Neoadjuvant Immunotherapy Combos Could Help Reshape Management of CRC

Stacey A. Cohen, MD, provides an overview on the current landscape of immunotherapies and prognostic tools in the treatment of colorectal cancer.

OncLive.com January 5, 2025

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC

Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.

OncLive.com January 5, 2025

FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC

The FDA has issued a CRL to the BLA seeking approval of subcutaneous amivantamab for use in patients with EGFR-mutated non–small cell lung cancer.

OncLive.com January 5, 2025

Advanced CML Patients Treated With Novel Three-Drug… : Oncology Times

An abstract is unavailable.

Oncology Times January 5, 2025

Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials

Investigators hope to add a treatment option that has the potential to produce superior efficacy vs present ROS1 inhibitors for patients with ROS1+ NSCLC.

OncLive.com January 5, 2025

Aspirin is associated with lower risk of pancreatic cancer and cancer-related mortality in patients with diabetes mellitus

Background Patients with type 2 diabetes mellitus (T2DM) have higher pancreatic cancer (PC) risk. While aspirin has chemopreventive effects on digestive cancers, its effect on…

OncoAlert January 4, 2025

Related Articles